Protective effects of 2,3-diaryl-substituted indole-based cyclooxygenase-2 inhibitors on oxidative modification of human low density lipoproteins in vitro

Clinical Hemorheology and Microcirculation

Volumn 61, Issue 4, 2016, Pages 615-632

  Pietzsch, Jens ^a,b   Laube, Markus ^a,b   Bechmann, Nicole ^a,b   Pietzsch, Franz Jacob ^a,b   Kniess, Torsten ^a,b  

^a INSTITUTE OF ION BEAM PHYSICS AND MATERIALS RESEARCH   (Germany)

^b DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

Antioxidants; atherogenesis; inflammation; lipid peroxidation; protein oxidation; radical scavenger; reactive oxygen species (ROS); selective cyclooxygenase 2 (COX 2) inhibitors (coxibs)

Indexed keywords

2,3 DIARYL INDOLE CYCLOOXYGENASE 2 INHIBITOR; ANTIOXIDANT; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDOLE DERIVATIVE; LOW DENSITY LIPOPROTEIN; MELATONIN; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG; OXIDIZED LOW DENSITY LIPOPROTEIN;

ANIMAL CELL; ANTIOXIDANT ACTIVITY; ARTICLE; ATHEROGENESIS; CELL ADHESION; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG POTENCY; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIPID OXIDATION; MACROPHAGE; MALE; NONHUMAN; RAT; THERAPEUTIC INDEX; ANIMAL; METABOLISM; OXIDATION REDUCTION REACTION; WISTAR FURTH RAT;

ANIMALS; ANTIOXIDANTS; CYCLOOXYGENASE 2 INHIBITORS; HUMANS; LIPOPROTEINS, LDL; MALE; OXIDATION-REDUCTION; RATS; RATS, INBRED WF; REACTIVE OXYGEN SPECIES;

EID: 84955091396     PISSN: 13860291     EISSN: 18758622     Source Type: Journal    
DOI: 10.3233/CH-141923     Document Type: Article

References (62)

1. J. Antosiewicz, E. Damiani, W. Jassem, M. Wozniak, M. Orena and L. Greci, Influence of structure on the antioxidant activity of indolinic nitroxide radicals, Free Radicals in Biology & Medicine 22 (1997), 249-255.
2. D. Bonnefont-Rousselot, G. Chevé, A. Gozzo, A. Tailleux, V. Guilloz, S. Caisey, E. Teissier, J.C. Fruchart, J. Delattre, D. Jore, D. Lesieur, P. Duriez and M. Gardès-Albert, Melatonin related compounds inhibit lipid peroxidation during copper or free radical-induced LDL oxidation, Journal of Pineal Research 33 (2002), 109-117.
3. K.Z. Boudjeltia, I. Legssyer, P. Van Antwerpen, R.L. Kisoka, S. Babar, N. Moguilevsky, P. Delree, J. Ducobu, C. Remacle, M. Vanhaeverbeek and D. Brohee, Triggering of inflammatory response by myeloperoxidase-oxidized LDL, Biochemistry and Cell Biology 84 (2006), 805-812.
4. G.E. Camí, M.E. Chacón Villalba, P. Colinas, G.A. Echeverría, G. Estiu and D.B. Soria, Crystal structure, spectroscopy and theoretical studies of p-cyanobenzenesulfonamide and a Cu(II) complex, Journal of Molecular Structure 1024 (2012), 110-116.
5. J.A. Campbell, V. Bordunov, C.A. Broka, M.F. Browner, J.M. Kress, T. Mirzadegan, C. Ramesha, B.F. Sanpablo, R. Stabler, P. Takahara, A. Villasenor, K.A. Walker, J.H. Wang, M. Welch and P. Weller, Rational design of 6-methylsulfonylindoles as selective cyclooxygenase-2 inhibitors, Bioorganic Medicinal Chemistry Letters 14 (2004), 4741-4745.
6. V. Capra, M. Bäck, S.S. Barbieri, M. Camera, E. Tremoli and G.E. Rovati, Eicosanoids and their drugs in cardiovascular diseases: Focus on atherosclerosis and stroke, Medicinal Research Reviews 33 (2013), 364-438.
7. F. Cipollone, G. Cicolini and M. Bucci, Cyclooxygenase and prostaglandin synthases in atherosclerosis: Recent insights and future perspectives, Pharmacology & Therapeutics 118 (2008), 161-180.
8. L. Cominacini, U. Garbin, A.F. Pasini, A. Davoli, M. Campagnola, A.M. Pastorino, G. Gaviraghi and V. Lo Cascio, Oxidized low-density lipoprotein increases the production of intracellular reactive oxygen species in endothelial cells: Inhibitory effect of lacidipine, Journal of Hypertension 16 (1998), 1913-1919.
9. D. Costa, L. Moutinho, J.L.F.C. Lima and E. Fernandes, Antioxidant activity and inhibition of human neutrophil oxidative burst mediated by arylpropionic acid non-steroidal anti-inflammatory drugs, Biological and Pharmaceutical Bulletin 29 (2006), 1659-1670.
10. S. Costa, F. Zimetti, M. Pedrelli, G. Cremonesi and F. Bernini, Manidipine reduces pro-inflammatory cytokines secretion in human endothelial cells and macrophages, Pharmacological Research 62 (2010), 265-270.
11. C. Crisafulli, M. Galuppo and S. Cuzzocrea, Effects of genetic and pharmacological inhibition of TNF-Alpha in the regulation of inflammation in macrophages, Pharmacological Research 60 (2009), 332-340.
12. A. Eldor, Z. Fuks, Y. Matzner, L.D. Witte and I. Vlodavsky, Perturbation of endothelial functions by ionizing irradiation: Effects on prostaglandins, chemoattractants and mitogens, Seminars in Thrombosis and Hemostasis 15 (1989), 215-225.
13. W. Erl, P.C.Weber and C.Weber, Monocytic cell adhesion to endothelial cells stimulated by oxidized lowdensity lipoprotein is mediated by distinct endothelial ligands, Atherosclerosis 136 (1998), 297-303.
14. H. Esterbauer, G. Striegl, H. Puhl and M. Rotheneder, Continuous monitoring of in vitro oxidation of human low density lipoprotein, Free Radical Research Communications 6 (1989), 67-75.
15. A. Gozzo, D. Lesieur, P. Duriez, J.C. Fruchart and E. Teissier, Structure-Activity relationships in a series of melatonin analogues with the low-density lipoprotein oxidation model, Free Radicals in Biology & Medicine 26 (1999), 1538-1543.
16. C. Haase-Kohn, S.Wolf, J. Lenk and J. Pietzsch, Copper-mediated cross-linking of S100A4, but not of S100A2, results in proinflammatory effects in melanoma cells, Biochemical and Biophysical Research Communications 413 (2011), 494-498.
17. B. Halliwell, J.M. Gutteridge and O.I. Aruoma, The deoxyribose method: A simple test-Tube assay for determination of rate constants for reactions of hydroxyl radicals, Analytical Biochemistry 165 (1987), 215-219.
18. S. Harirforoosh, W. Asghar and F. Jamali, Adverse effects of nonsteroidal antiinflammatory drugs: An update of gastrointestinal, cardiovascular and renal complications, Journal of Pharmacy & Pharmaceutical Sciences 16 (2013), 821-847.
19. S. Hoppmann, B. Steiniger, K. Strobel, C. Haase and J. Pietzsch, In vivo catabolism of hypochlorite-modified low density lipoproteins (LDL): Insights from small animal positron emission tomography studies, In: J. Pietzsch (ed.), Research Signpost, Trivandrum, India, 2006, pp. 197-219.
20. W. Hu, Z. Guo, F. Chu, A. Bai, X. Yi, G. Cheng and J. Li, Synthesis and biological evaluation of substituted 2-sulfonyl-phenyl-3-phenyl-indoles: A new series of selective COX-2 inhibitors, Bioorganic Medicinal Chemistry 11 (2003), 1153-1160.
21. J. Y. Im, D. Kim, S. G. Paik, and P. L. Han, Cyclooxygenase-2-dependent neuronal death proceeds via superoxide anion generation, Free Radical Biology and Medicine 41 (2006), 960-972.
22. B. Jawabrah Al-Hourani, S.K. Sharma, M. Suresh and F. Wuest, Cyclooxygenase-2 inhibitors: A literature and patent review (2009 -2010), Expert Opinion on Therapeutic Patents 21(9) (2011), 1339-1432.
23. N.V. Kaminskaia, G.M. Ullmann, D.B. Fulton and N.M. Kostic, Spectroscopic, kinetic, and mechanistic study of a new mode of coordination of indole derivatives to platinum(II) and palladium(II) ions in complexes, Inorganic Chemistry 39 (2000), 5004-5013.
24. M. R. Karekal, V. Biradar and M. Bennikallu Hire Mathada, Synthesis, characterization, antimicrobial, DNA cleavage, and antioxidant studies of some metal complexes derived from schiff base containing indole and quinoline moieties, Bioinorganic Chemistry and Applications 2013 (2013), 315972.
25. T. Kniess, M. Laube, R. Bergmann, F. Sehn, F. Graf, J. Steinbach, F.Wuest and J. Pietzsch, Radiosynthesis of a 18F-labeled 2, 3-diarylsubstituted indole via McMurry coupling for functional characterization of cyclooxygenase-2 (COX-2) in vitro and in vivo, Bioorganic Medicinal Chemistry 20 (2012), 3410-3421.
26. S. Kopprasch, W. Leonhardt, J. Pietzsch and H. Kühne, Hypochlorite-modified low-density lipoprotein stimulates human polymorphonuclear leukocytes for enhanced production of reactive oxygen metabolites, enzyme secretion, and adhesion to endothelial cells, Atherosclerosis 136 (1998), 315-324.
27. S. Kopprasch, J. Pietzsch and J. Grässler, The protective effects of HDL and its constituents against neutrophil respiratory burst activation by hypochlorite-oxidized LDL, Molecular and Cellular Biochemistry 258 (2004), 121-127.
28. S. Kopprasch, J. Pietzsch, T. Westendorf, H-J Kruse and J. Grässler, The pivotal role of scavenger receptor CD36 and phagocyte-derived oxidants in oxidized low density lipoprotein-induced adhesion to endothelial cells, The International Journal of Biochemistry & Cell Biology 36 (2004), 460-471.
29. S. Kopprasch, K. Richter, W. Leonhardt, J. Pietzsch and J. Grässler, Urate attenuates oxidation of native low-density lipoprotein by hypochlorite and the subsequent lipoprotein-induced respiratory burst activities of polymorphonuclear leukocytes, Molecular and Cellular Biochemistry 206 (2000), 51-56.
30. I. Kruk, H.Y. Aboul-Enein, T. Michalska, K. Lichszteld, K. Kubasik-Kladna and S. Olgen, In vitro scavenging activity for reactive oxygen species by N-substituted indole-2-carboxylic acid esters, Luminescence 22 (2007), 379-386.
31. D. Lapenna, G. Ciofani, D. Festi, M. Neri, S.D. Pierdomenico, M.A. Giamberardino and F. Cuccurullo, Antioxidant properties of ursodeoxycholic acid, Biochemical Pharmacology 64(11) (2002), 1661-1667.
32. M. Laube, T. Kniess and J. Pietzsch, Radiolabeled COX-2 inhibitors for non-invasive visualization of COX-2 expression and activity-A critical update, Molecules 18 (2013), 6311-6355.
33. M. Laube, C. Tondera, S.K. Sharma, N. Bechmann, F-J Pietzsch, A. Pigorsch, M. Köckerling, F. Wuest, J. Pietzsch and T. Kniess, 2, 3-Diaryl-substituted indole based COX-2 inhibitors as leads for imaging tracer development, RSC Advances 4 (2014), 38726-38742.
34. D. Lussi, A. Potapovich, M. Riccardo, E. Dellambra, G. Pressi, V. Kostyuk, R. Dal Toso, C. De Luca, S. Pastore and L. Korkina, Anti-inflammatory effects of concentrated ethanol extracts of Edelweiss (Leontopodium alpinum Cass.) callus cultures towards human keratinocytes and endothelial cells, Mediators of Inflammation 2012 (2012), 498373.
35. L.J. Marnett, The COXIB experience: A look in the rearview mirror, Annual Review of Pharmacology and Toxicology 49 (2009), 265-290.
36. C. Mazière and J.C. Mazière, Activation of transcription factors and gene expression by oxidized low-density lipoprotein, Free Radicals in Biology & Medicine 46 (2009), 127-137.
37. D. Mukherjee, S.E. Nissen and E.J. Topol, Risk of cardiovascular events associated with selective COX-2 inhibitors, Journal oft the American Medical Association 286 (2001), 954-959.
38. A. Oguogho, H. Kritz, O. Wagner and H. Sinzinger, 6-oxo-PGF1- and 8-epi-PGF2 in the arterial wall layers of various species: A comparison between intact and atherosclerotic areas, Prostaglandins, Leukotrienes & Essential Fatty Acids 64 (2001), 167-171.
39. T.D. Penning, J.J. Talley, S.R. Bertenshaw, J.S. Carter, P.W. Collins, S. Docter, M.J. Graneto, L.F. Lee, J.W. Malecha, J.M. Miyashiro, R.S. Rogers, D.J. Rogier, S.S. Yu, G.D. Anderson, E.G. Burton, J.N. Cogburn, S.A. Gregory, C.M. Koboldt, W.E. Perkins, K. Seibert, A.W. Veenhuizen, Y.Y. Zhang and P.C. Isakson, Synthesis and biological evaluation of the 1, 5-diarylpyrazole class of cyclooxygenase-2 inhibitors: Identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib), Journal of Medicinal Chemistry 40 (1997), 1347-1365.
40. J. Pietzsch, Measurement of 5-hydroxy-2-Aminovaleric acid as a specific marker of iron-mediated oxidation of proline and arginine side-chain residues of low-density lipoprotein apolipoprotein B-100, Biochemical and Biophysical Research Communications 270 (2000), 852-857.
41. J. Pietzsch, R. Bergmann, K. Rode, C. Hultsch, B. Pawelke, F. Wuest and J. van den Hoff, Fluorine-18 radiolabeling of low density lipoproteins (LDL): A potential approach for characterization and differentiation of metabolism of native and oxidized LDL in vivo, Nuclear Medicine and Biology 31 (2004), 1043-1050.
42. J. Pietzsch, R. Bergmann, F. Wuest, B. Pawelke, C. Hultsch and J. van den Hoff, Catabolism of native and oxidized low density lipoproteins: In vivo insights from small animal positron emission tomography studies, Amino Acids 29 (2005), 389-404.
43. J. Pietzsch, J., S. Kopprasch and R. Bergmann, Analysis of 3-chlorotyrosine as a specific marker of protein oxidation: The use of N(O, S)-ethoxycarbonyltrifluoroethyl ester derivatives and gas chromatography/mass spectrometry, Rapid Communications in Mass Spectrometry 17 (2003), 767-770.
44. J. Pietzsch, M. Laube, F.J. Pietzsch, R. Bergmann and T. Kniess, Concomitant targeting of cyclooxygenase-2 and oxidant stress pathways for radioprotection of endothelial cells, In: B.S. Lewis, M.Y. Flugelman and D.A. Halon (eds.), Medimond S.r.l -Monduzzi Editore International, Bologna, Italy, 2011, pp. 107-110.
45. D. Praticò, Prostanoid and isoprostanoid pathways in atherogenesis, Atherosclerosis 201 (2008), 8-16.
46. D. Praticò, J.A. Lawson, J. Rokach and G.A. FitzGerald, The isoprostanes in biology and medicine, Trends in Endocrinology & Metabolism 12 (2001), 243-247.
47. E.D. Reis, M. Roque, H. Dansky, J.T. Fallon, J.J. Badimon, C. Cordon-Cardo, S.J. Shiff and E.A. Fisher, Sulindac inhibits neointimal formation after arterial injury in wild-Type and apolipoprotein E-deficient mice, Proceedings of the National Academy of Sciences USA 97 (2000), 12764-12769.
48. F. Robbesyn, R. Salvayre and A. Negre-Salvayre, Dual role of oxidized LDL on the NF-kappaB signaling pathway, Free Radical Research 38 (2004), 541-551.
49. H. Seeger, A.O. Mueck and T.H. Lippert, Effect of melatonin and metabolites on copper-mediated oxidation of low density lipoprotein, British Journal of Clinical Pharmacology 44 (1997), 283-284.
50. D.L. Simmons, R.M. Botting and T. Hla, Cyclooxygenase isozymes: The biology of prostaglandin synthesis and inhibition, Pharmacological Reviews 56 (2004), 387-437.
51. Y. Steffen, T. Schewe and H. Sies, Epicatechin protects endothelial cells against oxidized LDL and maintains NO synthase, Biochemical and Biophysical Research Communications 331 (2005), 1277-1283.
52. D. Steinberg, S. Parthasarathy, T.E. Carew, J.C. Khoo and J.L.Witztum, Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity, The New England Journal of Medicine 320 (1989), 915-924.
53. S. Suzen, P. Bozkaya, T. Coban and D. Nebioʇlu, Investigation of the in vitro antioxidant behaviour of some 2-phenylindole derivatives: Discussion on possible antioxidant mechanisms and comparison with melatonin, Journal of Enzyme Inhibition and Medicinal Chemistry 21 (2006), 4405-4411.
54. R. Terkeltaub, C.L. Banka, J. Solan, D. Santoro, K. Brand and L.K. Curtiss, Oxidized LDL induces monocytic cell expression of interleukin-8, a chemokine with T-lymphocyte chemotactic activity, Arteriosclerosis and Thrombosis 14 (1994), 47-53.
55. S. Ullm, M. Laube, N. Bechmann, T. Kniess and J. Pietzsch, Organotypical vascular model for characterization of radioprotective compounds: Studies on antioxidant 2, 3-diaryl-substituted indole-based cyclooxygenase-2 inhibitors, Clinical Hemorheology and Microcirculation 58 (2014), 281-295.
56. S. Ullm, F. Sehn, M. Laube, C. Tondera, N. Bechmann, B. Mosch, T. Kniess and J. Pietzsch, Targeting cyclooxygenase-2 and oxidant stress pathways for attenuation of radiation-induced vascular dysfunction, In: A. Zarzuelo and R. Jimenez (eds.), Medimond S.r.l -Monduzzi Editore International, Bologna, Italy, 2013, pp. 87-90.
57. A.A. Vaporciyan, M.L. Jones and P.A.Ward, Rapid analysis of leukocyte-endothelial adhesion, Journal of Immunological Methods 159 (1993), 93-100.
58. M.F. Walter, R.F. Jacob, C.A. Day, R. Dahlborg, Y. Weng and R.P. Mason, Sulfone COX-2 inhibitors increase susceptibility of human LDL and plasma to oxidative modification: Comparison to sulfonamide COX-2 inhibitors and NSAIDs, Atherosclerosis 177 (2004), 235-243.
59. E. Walters-Laporte, C. Furman, S. Fouquet, F. Martin-Nizard, S. Lestavel, A. Gozzo, D. Lesieur, J.C. Fruchart, P. Duriez and E. Teissier, A high concentration of melatonin inhibits in vitro LDL peroxidation but not oxidized LDL toxicity toward cultured endothelial cells, Journal of Cardiovascular Pharmacology 32 (1998), 582-592.
60. K.M.Wasan, D.R. Brocks, S.D. Lee, K. Sachs-Barrable and S.J. Thornton, Impact of lipoproteins on the biological activity and disposition of hydrophobic drugs: Implications for drug discovery, Nature Reviews Drug Discovery 7 (2008), 84-99.
61. Y. You, J. Wang, Y. Tong, Q. Hao, Y. Li, H. Yang, L. Huang and F. Liao, Anti-inflammatory effect of acetylharpagide demonstrated by its influence on leukocyte adhesion and transmigration in endothelial cells under controlled shear stress, Clinical Hemorheology and Microcirculation 56 (2014), 205-217.
62. C. Zhang, The role of inflammatory cytokines in endothelial dysfunction, Basic Research in Cardiology 103 (2008), 398-406.